NCT00667173已完成2 期
A Phase 2, Multi-Center, Evaluator-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-115 in the Treatment of Rosacea
Dow Pharmaceutical Sciences10 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 140
- 试验地点
- 10
- 主要终点
- Change from baseline in the number of inflammatory lesions
研究概览
简要总结
The purpose of this study is to assess the safety and effectiveness of IDP-115 in treating patients with rosacea.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of facial rosacea
- •Presence of inflammatory lesions
排除标准
- •Dermatological conditions of the face that could interfere with clinical evaluations
- •Known history of photosensitivity disorders (such as lupus erythematosus or polymorphous light eruption)
- •Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
研究组 & 干预措施
1
Experimental
干预措施: IDP-115 (Drug)
2
Placebo Comparator
干预措施: Vehicle (Drug)
3
Placebo Comparator
干预措施: Vehicle (Drug)
结局指标
主要结局
Change from baseline in the number of inflammatory lesions
时间窗: 12 weeks
Improvement from baseline in global severity
时间窗: 12 weeks
次要结局
- Change from baseline in erythema(12 weeks)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne VulgarisAcne VulgarisNCT00666900Dow Pharmaceutical Sciences366
Unknown
2 期
A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne VulgarisAcne VulgarisNCT02537483Valeant Pharmaceuticals350
Unknown
3 期
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne VulgarisAcne VulgarisNCT02491060Valeant Pharmaceuticals800
Unknown
3 期
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne VulgarisAcne VulgarisNCT02535871Valeant Pharmaceuticals800
已完成
2 期
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque PsoriasisPsoriasisNCT05003531Innovent Biologics (Suzhou) Co. Ltd.250